847 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by DSG Capital Advisors LLC

DSG Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 847 shares of the biopharmaceutical company's stock, valued at approximately $603,000.

Several other hedge funds also recently modified their holdings of REGN. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $25,000. OFI Invest Asset Management bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth $28,000. Rakuten Securities Inc. raised its position in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the last quarter. Avalon Trust Co bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth $36,000. Finally, Crowley Wealth Management Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $36,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded down $112.15 during midday trading on Friday, reaching $493.24. The company's stock had a trading volume of 6,307,887 shares, compared to its average volume of 829,478. Regeneron Pharmaceuticals, Inc. has a 12-month low of $485.00 and a 12-month high of $1,211.20. The firm has a 50 day moving average price of $584.25 and a 200-day moving average price of $667.42. The stock has a market capitalization of $53.25 billion, a P/E ratio of 12.89, a PEG ratio of 2.34 and a beta of 0.43. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter in the previous year, the firm earned $9.55 EPS. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% on a year-over-year basis. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.71%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on REGN. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Bernstein Bank lowered their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Cantor Fitzgerald started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 target price for the company. BMO Capital Markets reduced their target price on Regeneron Pharmaceuticals from $865.00 to $800.00 and set an "outperform" rating for the company in a research note on Wednesday, April 30th. Finally, Royal Bank of Canada downgraded Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price for the company. in a research note on Friday. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $874.56.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.